In the last financial year 2025, India’s Pharmaceutical Market (IPM) increased by 8.4 percent. According to the market research firm Farmarack, this increased IPM has increased due to the positive price increase in major treatments.
The best performing remedies recorded an increase of 10.8 percent in heart disease. This was followed by a price increase of 10.2 per cent in the gastrointestinal and 8 per cent in the non -diabetic section. These three sections stake in the total selling price of the pharma market about 34 per cent, which increased the total business in IPM to more than Rs 2.25 lakh crore, while units in the domestic market increased by 1.2 per cent.
In the financial year 2025, the serious disease segment performed strongly and the GSK antibiotic drug augmentin remained the best selling drug with sales of Rs 816 crore during the last 12 months. The sales of the Diabetic Glycomat GV of the Bada USV were Rs 803 crore.
Even though this growth was value based, but two major incidents such as diabetes molecule Empagliflogen in March and offering of anti -obesity drugs in India affected the market Also done.
Vice President (Commercial), Vice President (Commercial) of Farmarack, said that about 86 brands of 19 companies have started the Empagliflogen Plain and Combination facility with the end of the specialty of the molecules. “Molecule declined in March this year compared to a sharp increase in the volume of the brand, which shows a strong value difference in branded generic medicines compared to the innovator brand,” he said. For example, after the patent is over, the price of Empagliflogen Plane has been reduced by about 85 per cent, which has come down from Rs 60 to 70 per tablet to Rs 5 to 15 per tablet.
First Published – April 8, 2025 | 10:45 pm IST